Novo Nordisk reveals staggering interim profits

In the first half of 2015, the global leader in insulin and diabetes care increased its sales by 25 percent

The Danish pharmaceutical giant Novo Nordisk increased its operating profit by 57 percent in the first six months of 2015 to 26.3 billion kroner.

The company’s sales increased by 25 percent to 52.3 billion kroner in the same period.

The global leader in insulin and diabetes care has come a long way since 1989 when two small Danish companies, Nordisk Insulin Laboratory and Novo Therapeutic Laboratory, merged.

Large market value
Novo Nordisk is Denmark’s largest company by market value, which is currently assessed by Citibank to be about 2,300 billion kroner.

The company employs some 40,000 employees worldwide, of which 16,669 (42 percent) are employed in Denmark.

While the headquarters are located in Denmark, the company has manufacturing facilities in seven other countries and subsidiaries or offices in 74 countries.





  • How internationals can benefit from joining trade unions

    How internationals can benefit from joining trade unions

    Being part of a trade union is a long-established norm for Danes. But many internationals do not join unions – instead enduring workers’ rights violations. Find out how joining a union could benefit you, and how to go about it.

  • Internationals in Denmark rarely join a trade union

    Internationals in Denmark rarely join a trade union

    Internationals are overrepresented in the lowest-paid fields of agriculture, transport, cleaning, hotels and restaurants, and construction – industries that classically lack collective agreements. A new analysis from the Workers’ Union’s Business Council suggests that internationals rarely join trade unions – but if they did, it would generate better industry standards.

  • Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    Novo Nordisk overtakes LEGO as the most desirable future workplace amongst university students

    The numbers are especially striking amongst the 3,477 business and economics students polled, of whom 31 percent elected Novo Nordisk as their favorite, compared with 20 percent last year.